Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Biologix Attends Middle East Pharmacoeconomics and Drug Policy Summit in Dubai
On April 28th and 29th 2023, Biologix team attended the Middle East Pharmacoeconomics and Drug Policy Summit in Dubai.
Regional Physicians’ Academy for Cardiovascular Education (PACE 1-RRR) Advances in Residual Risk Reduction Efforts
Biologix recently organized the Physicians’ Academy for Cardiovascular Education 1 - Residual Risk Reduction (PACE 1-RRR) on 9 and 10 June 2023 at Voco Hotel in Dubai, United Arab Emirates.
Biologix at Menactrims congress
Biologix has participated in the 7th Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS) Congress ... Read More
